64cu-llp2a
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 20, 2018 (NCT03804424)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06636175 | Early Phase 1 (Phase 1) | Nov 30, 2024 | Washington University in St. Louis |
| NCT04925492 | Phase 1 | Aug 15, 2021 | The Pittsburgh Foundation, University of Pittsburgh |
| NCT03804424 | Early Phase 1 (Phase 1) | Nov 20, 2018 | Washington University in St. Louis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Washington University in St. Louis | Academic/Hospital | 2 | 2 | 1 | 2018 |
| The Pittsburgh Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1